Market open
Arcturus Therapeutics Holdings/$ARCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
Ticker
$ARCT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
175
ISIN
US03969T1097
Website
ARCT Metrics
BasicAdvanced
$294M
-
-$2.52
2.37
-
Price and volume
Market cap
$294M
Beta
2.37
52-week high
$45.00
52-week low
$8.04
Average daily volume
446K
Financial strength
Current ratio
5.643
Quick ratio
4.686
Long term debt to equity
16.678
Total debt to equity
18.249
Management effectiveness
Return on assets (TTM)
-13.67%
Return on equity (TTM)
-27.40%
Valuation
Price to revenue (TTM)
2.041
Price to book
1.26
Price to tangible book (TTM)
1.26
Price to free cash flow (TTM)
-3.263
Growth
Revenue change (TTM)
15.38%
Earnings per share change (TTM)
-37.27%
3-year revenue growth (CAGR)
110.17%
3-year earnings per share growth (CAGR)
-30.56%
What the Analysts think about ARCT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Arcturus Therapeutics Holdings stock.
ARCT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ARCT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ARCT News
AllArticlesVideos
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript
Seeking Alpha·3 days ago
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
Business Wire·3 weeks ago
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Arcturus Therapeutics Holdings stock?
Arcturus Therapeutics Holdings (ARCT) has a market cap of $294M as of May 15, 2025.
What is the P/E ratio for Arcturus Therapeutics Holdings stock?
The price to earnings (P/E) ratio for Arcturus Therapeutics Holdings (ARCT) stock is 0 as of May 15, 2025.
Does Arcturus Therapeutics Holdings stock pay dividends?
No, Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Arcturus Therapeutics Holdings dividend payment date?
Arcturus Therapeutics Holdings (ARCT) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcturus Therapeutics Holdings?
Arcturus Therapeutics Holdings (ARCT) has a beta rating of 2.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.